Text and Data Mining valid from 2018-09-06
Received: 22 June 2018
Revised: 12 August 2018
Accepted: 15 August 2018
First Online: 6 September 2018
Change Date: 7 December 2018
Change Type: Correction
Change Details: This article was originally published under standard licence, but has now been made available under a [CC BY 4.0] license. The PDF and HTML versions of the paper have been modified accordingly.
: PJK is a co-founder and shareholder in Eolas Therapeutics Inc., has a patent license agreement with AstraZeneca, receives research support from Eli Lilly, and has received consulting fees from Takenda Pharmaceuticals, USA. PCF has received consulting fees from GlaxoSmithKline.